Угода про спільну лікарську терапію — the formal legal instrument that lets a pharmacist initiate, adjust, or discontinue therapy within a physician-defined scope
A collaborative drug therapy agreement (CDTA) — sometimes called a collaborative practice agreement (CPA) — is a formal, written legal instrument executed between a licensed physician (or physician group) and a pharmacist. It authorizes the pharmacist to perform specific clinical functions beyond routine dispensing: initiating drug therapy, adjusting doses, ordering associated laboratory tests, and discontinuing therapy, all within limits the physician has explicitly approved in advance. The agreement does not transform the pharmacist into an independent prescriber; it delegates a bounded slice of clinical decision-making under a framework of physician oversight defined by state or provincial pharmacy practice acts.
A CDTA is not a certification, a license, or a scope-of-practice expansion granted by a licensing board in isolation — it is a private, bilateral contract that operates inside boundaries set by statute:
• Enabling statute: state pharmacy practice acts (and often companion medical practice acts) must first authorize collaborative practice before any agreement can be signed — without enabling legislation, no CDTA is legally valid regardless of what it says. • Bilateral instrument: the agreement is executed between one or more named physicians and one or more named pharmacists (or a pharmacist role at a defined practice site); it is not a blanket authority extending to any pharmacist anywhere. • Delegated, not independent, authority: every action the pharmacist takes under the agreement is legally understood as occurring under the collaborating physician's ongoing responsibility for the patient's care — the physician retains ultimate clinical accountability. • Site- and role-specific: agreements are commonly anchored to a specific practice setting (an ambulatory clinic, a health-system pharmacy, an anticoagulation clinic) rather than following the pharmacist across every practice environment.
The agreement itself is a written document, typically several pages, that must be signed, dated, kept on file, and made available for regulatory inspection. It sits alongside — but does not replace — the pharmacist's underlying professional license.
A CDTA authorizes a defined pharmacist to perform defined activities for a defined patient population under a defined physician's ongoing oversight — remove any one of those four boundaries and the arrangement is no longer what the statute contemplated.
Collaborative practice law emerged to address a structural mismatch: pharmacists are the most frequently accessible healthcare professionals, often see patients more regularly than physicians for chronic disease management, and hold deep, current knowledge of pharmacology, drug interactions, and dosing — yet traditional scope-of-practice rules confined them to dispensing and counseling.
CDTAs resolve this by allowing physicians to formally delegate specific, repetitive, protocol-driven clinical tasks (titrating a statin to a target LDL, adjusting warfarin dose to an INR range, refilling and adjusting an inhaled corticosteroid based on symptom control) to a pharmacist who can act more immediately, without requiring a physician visit for every dose change. The physician defines the guardrails once, in writing, rather than approving each individual adjustment in real time.
This legal architecture is deliberately conservative: authority flows downward from statute to agreement to individual pharmacist action, and every layer can be audited independently.
The single most important function of a collaborative drug therapy agreement is precision: it must specify exactly which activities the pharmacist may perform, for which medications or drug classes, and under what clinical conditions. A well-drafted agreement reads less like a general grant of trust and more like a technical specification — because ambiguity in scope is the single largest source of both clinical risk and legal exposure for both parties.
Most agreements enumerate authorized pharmacist activities from a fairly standard menu, each of which can be granted, restricted, or withheld independently:
• Therapy initiation: starting a new medication for a diagnosed condition already established by the physician (e.g., starting an ACE inhibitor once hypertension is diagnosed and a treatment protocol is agreed). • Dose adjustment / titration: modifying dose, frequency, or formulation of an already-prescribed medication in response to lab values, symptom control, or side effects — usually the most heavily used authority. • Ordering and interpreting associated labs: ordering routine monitoring tests directly tied to the therapy being managed (INR, renal function, lipid panel, HbA1c) without a separate physician order each time. • Therapeutic substitution: switching between agents within an approved therapeutic class under a defined protocol. • Discontinuation: stopping therapy when it is no longer indicated, ineffective, or causing harm. • Patient education and self-management counseling tied to the above.
What is almost never included, absent extraordinary statutory allowance, is diagnostic authority — the pharmacist acts on a diagnosis the physician has already made, not to establish a new one.
Precision in drafting matters because the agreement functions as the operative legal boundary of the pharmacist's delegated authority for every subsequent encounter:
• Named medications or classes: agreements list specific drugs or a bounded therapeutic class (e.g., "oral anticoagulants for atrial fibrillation") rather than open-ended language. • Quantitative limits: dose ranges, maximum titration steps per visit, or lab-value thresholds that trigger mandatory physician consultation before further action. • Clinical condition gates: authority may apply only when the patient is clinically stable, only for follow-up visits (not new patient encounters), or only within a specified diagnosis. • Explicit exclusions: high-risk scenarios — pregnancy, pediatric patients, specific comorbidities, signs of an adverse reaction — are frequently carved out and require immediate physician involvement rather than pharmacist action.
Any proposed pharmacist activity that falls outside these enumerated boundaries is, by definition, not authorized under the agreement — regardless of the pharmacist's clinical judgment about whether the action would be reasonable. The whole point of a bounded scope is that the physician has pre-approved specific actions, not the pharmacist's general competence.
A pharmacist who is well within their professional competence to make a clinical judgment may still be outside the agreement's authorized scope for that specific action — competence and authorization are legally distinct, and only the latter is governed by the CDTA.
Collaborative drug therapy agreements are almost never written to apply universally across a physician's entire patient panel. Instead, they are typically scoped to a specific patient population (e.g., adults with type 2 diabetes at a particular clinic) and a specific clinical condition or therapeutic area. This specificity reflects two converging factors: the collaborating physician's comfort delegating authority for that condition, and the pharmacist's demonstrated expertise and training in managing it.
Physicians extend collaborative authority in proportion to the trust they have built with a specific pharmacist for a specific clinical domain — not as a generic professional courtesy:
• Track record: many agreements formalize a working relationship that already existed informally, after the physician has observed the pharmacist's judgment over time in a particular therapeutic area. • Specialty training and credentials: board certification (e.g., Board Certified Ambulatory Care Pharmacist, Board Certified Pharmacotherapy Specialist), postgraduate residency training, or condition-specific certificate programs (anticoagulation management, diabetes education) are frequently prerequisites named directly in the agreement. • Practice-site alignment: a pharmacist embedded in a cardiology clinic may hold collaborative authority for lipid and anticoagulation management there, while a different agreement — or none at all — governs their authority in an unrelated setting.
This is why a single pharmacist may hold several distinct CDTAs simultaneously, each with a different collaborating physician, a different patient population, and a different therapeutic scope — they do not merge into one general authority.
Narrowing the patient population is itself a risk-control mechanism, independent of the drug-class restrictions covered in the scope of activities:
• Stable, protocolizable conditions: chronic, well-characterized conditions with established monitoring parameters (INR ranges, HbA1c targets, blood pressure goals) lend themselves to protocol-driven management and are the most common CDTA subject matter. • Explicit population exclusions: pediatric patients, pregnant patients, patients with unstable or rapidly evolving conditions, and patients with significant comorbid complexity are frequently excluded even when the underlying condition would otherwise be in scope. • Setting-bound eligibility: some agreements apply only to patients already established in a specific clinic or health system, explicitly excluding walk-in or unfamiliar patients where less clinical history is available.
The underlying logic is consistent with the rest of the CDTA structure: authority is calibrated to the situations where the physician has the highest confidence that a pharmacist, acting within a protocol, will reach the same clinical decision the physician would have reached personally.
The same pharmacist may be fully authorized to adjust warfarin dosing for an established anticoagulation-clinic patient and simultaneously have zero authority to do the same for a walk-in patient outside that population — the agreement travels with the defined population, not with the pharmacist's general skill set.
Delegated authority does not mean unsupervised authority. Every collaborative drug therapy agreement specifies documentation and communication requirements that preserve the collaborating physician's ongoing oversight of the patient's care — how the pharmacist's actions must be recorded, how quickly and through what channel the physician must be informed, and what triggers an immediate versus a routine notification.
Because the collaborating physician is not present for each individual pharmacist action, documentation is the primary mechanism by which oversight is actually exercised in practice, rather than existing only on paper:
• Contemporaneous chart notes: pharmacist actions taken under the agreement are recorded in the shared medical record — typically the same electronic health record the physician uses — at the time of the encounter, not after the fact. • Standardized note content: agreements often specify what must be documented for each action: the clinical rationale, the specific change made, relevant lab or vital sign data that supported the decision, and any patient counseling provided. • Attribution: notes must clearly identify that the action was taken by the pharmacist under the specific collaborative agreement, so the physician (and any subsequent reviewer) can trace authority back to its source.
Without this discipline, the physician has no practical way to exercise the oversight the law requires them to retain — documentation is what makes delegated authority auditable in real time rather than only in retrospect.
Agreements typically define at least two distinct communication tracks:
• Routine communication: for actions within expected parameters (a dose titration that proceeded exactly as the protocol anticipated), the physician is informed through the standard chart note, reviewed on a normal clinical cadence — daily inbox review, weekly panel review, or at the patient's next physician visit. • Urgent / escalation communication: findings outside expected parameters — a critically abnormal lab value, a significant adverse drug reaction, a clinical status change — require direct, often same-day communication to the physician by phone, secure message, or in-person conversation, in addition to the chart note. • Periodic aggregate reporting: some agreements additionally require the pharmacist to provide the physician with a periodic summary of all actions taken under the agreement (e.g., monthly or quarterly), giving the physician a pattern-level view that individual chart notes do not provide on their own.
The existence of these defined pathways is itself part of what makes a CDTA legally defensible: regulators and courts look for evidence that oversight was structurally built into the arrangement, not merely assumed.
A pharmacist can be acting entirely within the agreement's authorized scope and still be out of compliance with the agreement if the required documentation or notification does not occur — scope and communication are independent obligations that must both be satisfied.
A collaborative drug therapy agreement is not a permanent, static grant of authority. It is periodically reviewed and renewed — commonly on an annual or biennial cycle, though state law and institutional policy vary — allowing the collaborating physician and pharmacist to adjust the scope based on accumulated experience, and ensuring the arrangement remains current with evolving guidelines, staffing, and practice patterns.
A review is a structured checkpoint, not a rubber stamp — both parties are expected to actually reassess whether the current terms remain appropriate:
• Outcomes review: how patients managed under the agreement have fared — whether target clinical outcomes (INR time-in-range, HbA1c control, blood pressure control) were achieved, and whether any adverse events or near-misses occurred. • Scope calibration: based on this track record, the physician may expand the pharmacist's authorized activities (adding a new drug class, raising a dose-adjustment ceiling), narrow it (removing an activity that proved problematic), or leave it unchanged. • Currency check: the agreement is checked against current clinical guidelines, updated formularies, changes in either party's credentials or practice site, and any changes in the underlying enabling statute or regulatory requirements. • Re-signature: a renewed agreement is formally re-executed — signed and dated again — rather than assumed to continue automatically, creating a clear, auditable record of an active, current agreement at any point in time.
Because a CDTA's authority is legally grounded in the specific, current, signed document, an agreement that has passed its review date without renewal is a compliance risk even if nothing about the clinical relationship has actually changed:
• No automatic extension: in most frameworks, an expired or long-overdue agreement does not silently continue — pharmacist actions taken under a lapsed agreement can fall outside the pharmacist's legal authority, exposing both parties to liability. • Administrative tracking: health systems and pharmacy departments typically maintain a registry of active agreements with renewal due-dates, precisely because relying on informal memory is unreliable at scale. • A conservative operating rule: many programs treat an agreement that is significantly overdue for review (illustratively, around 12 months without a check-in, depending on the jurisdiction's actual requirement) as a signal to pause reliance on the broadest elements of the scope until the review is completed — even though the agreement has not technically expired under every framework.
The renewal cycle closes the loop on the entire collaborative practice structure: statute enables it, the agreement defines it, documentation makes it auditable, and periodic review keeps it honest over time.
Treat "time since last review" as an operational early-warning signal, not a legal expiration date in every jurisdiction — but as agreements age well past their intended review interval, the prudent default is to flag them for renewal rather than assume the original terms still fit current practice.